Key terms
About PDSB
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PDSB news
Yesterday
8:11am ET
PDS Biotechnology to host KOL event on Phase 2 VERSATILE-002 trial
Mar 28
8:54am ET
PDS Biotechnology price target lowered to $11 from $14 at B. Riley
Mar 28
8:25am ET
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)
Mar 28
7:25am ET
PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success
Mar 28
7:05am ET
PDS Biotechnology price target lowered to $5 from $16 at Alliance Global Partners
Mar 27
7:36am ET
PDS Biotechnology reports 2023 EPS ($1.39), consensus ($1.46)
Mar 27
7:34am ET
PDS Biotechnology to prioritize triple combination in place of VERSATILE-003
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 13
8:23am ET
PDS Biotechnology announces publication of research, patent grant
No recent press releases are available for PDSB
PDSB Financials
Key terms
Ad Feedback
PDSB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PDSB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range